Twentieth-Fourth Annual Discovery on Target Meeting

Cambridge Healthtech Institute held its annual Discovery on Target (DoT) meeting in Boston last week. Attendance may have set a record, with over 1000 participants. There were sessions on antibodies, conjugates, and radioligands, but I’ll just touch on some of the small molecule themes most relevant to this blog.

 

Covalent approaches

As with last year, covalent approaches to drug discovery were well-represented. Dhirendra Simanshu (Frederick National Laboratory) described several drugs birthed in the NCI RAS Initiative, including ones targeting the G12C mutant of KRAS and C242 on the RAS-binding domain of PI3Kα. He also described how various KRAS mutants cause resistance to drugs, finding that most of them affect the K_I term (binding) more than the k_inact term (bonding). Continuing on the KRAS theme, Jack Sloan discussed efforts at BMS to discover inhibitors targeting both the on- and off-states of KRAS G12C.

 

Kasia Handing (Tango Therapeutics) presented both covalent and non-covalent approaches against VRK1, a synthetic lethal target for glioblastoma. A biochemical screen yielded covalent inhibitors that were characterized crystallographically, but they turned out to be too non-selective to progress. In the meantime, an in-cell DNA-encoded library (DEL) screen led to more advanceable molecules.

 

DEL was indeed a major topic of the conference, and here too covalent approaches are being explored. Elizabeth D’ambrosio described how GSK is identifying covalent binders from DEL screens, a process which includes testing for time-dependence as well as aggressive washing steps under denaturing conditions to quench unreacted molecules and wash away any sticky, non-covalently bound compounds. And Xiaojie Bruce Lu (Chinese Academy of Sciences) described applying DEL to a variety of targets, including some covalently targeting non-cysteine residues.

 

One of the advantages of DEL is being able to screen large libraries, and increasing throughput is also of interest to Harvard’s Steve Gygi, who is screening covalent fragments against cells and cell lysates. In 2024 we described how he was using tandem mass tag (TMT) multiplexing to analyze 18 samples in a single mass-spectrometry run, and he has now extended this to 35 samples. What’s more, Steve is combining 16 different fragments in each sample and introducing clever deconvolution approaches to further accelerate the process.

 

Not everyone is targeting cysteine residues. Mark Tye described the discovery of Revolution Medicines’ zoldonrasib, which uses an aziridine warhead to target the G12D mutant of KRAS. And Balyn Zaro (University of California San Francisco) described using ninhydrin derivatives to target arginine. Most organic chemists are familiar with ninhydrin’s reaction with primary amines such as the N-termini of peptides, but Balyn has been able to optimize selectivity for arginine and has used the resulting chemical probes to identify more than 7000 arginine residues in cells, about 5% of which are hyperreactive. Interestingly, some cell lines seem to have a greater proportion of reactive arginine residues than others.

 

Direct-to-Biology (D2B) approaches

Another recurring theme was direct-to-biology, in which crude reaction mixtures are screened directly in various assays without purification. Indeed, Nicholas Bland of Domainex said that after looking at the agenda of the meeting he considered skipping the introductory slides – and this was on the first official day of the conference. Nicholas described using D2B for optimizing PROTACs as well as for improving fragment hits against the GPCR A_2A receptor.

 

Jack Sadowsky, who also presented at DDC this past spring, described how he and his colleagues at Kimia are using D2B in combination with machine learning to develop selective inhibitors of kinases while also improving their in vitro ADME properties. This effort entailed making and testing tens of thousands of compounds from a virtual space of some 80 million molecules.

 

But even small-scale D2B can be valuable. Trevor Sherwood described how he and his colleagues at BMS used D2B to make and test 663 molecules to improve the potency of an EP4 agonist identified from a high-throughput screen. This involved multiple reaction types, including photoredox chemistry, for which they built a custom-designed reactor to evenly heat and illuminate the microtiter plates. The D2B work was done in parallel with medicinal chemistry, but interestingly the development candidate BMS-986526 came directly from the D2B work and has entered a phase 1/2a trial for rheumatoid arthritis.

 

There were other talks and posters on D2B that I missed, but I did attend two breakfast roundtables on the topic that were quite lively despite happening at 7:30 – a testament to the interest in the topic.

 

“Traditional” fragment-based drug discovery

At a plenary panel moderated by Drug Hunter’s Dennis Hu on drugging difficult targets, Biogen’s Klaus Urbahns asked the other panelists if they were still doing fragment-based lead discovery. John Tallarico of Novartis and Ian Storer of AstraZeneca immediately said yes. And in a separate presentation, Kris Borzilleri described how she and her Pfizer colleagues used fluorine-detected NMR and fragment optimization to identify ligands for an orphan GPCR.

 

Debanu Das described using high-throughput crystallography screening at XPose Therapeutics, now part of Mid-Atlantic BioTherapeutics, to identify inhibitors of DNA damage response pathway proteins. Although the initial hits had no detectable activity, SAR by catalog was able to get to nanomolar inhibitors of the protein APE1, which is overexpressed in ovarian cancer, in a matter of weeks.

 

But perhaps the most robust validation of FBDD was provided by Steve Fesik of Vanderbilt, who described a decades-long effort to drug the MYC pathway, which is probably dysregulated in almost all cancers. We described some of his published work on WDR5 here, but he is now making progress against MYC itself. This has not been easy: MYC is intrinsically disordered, and SAR-by-NMR screens against both the transactivation domain and the DNA-binding domain failed. However, MYC forms a structured leucine-zipper heterodimer with the protein MAX, and screening this complex yielded hits at the DNA binding interface. (Earlier this year we described work from Novartis on a different leucine zipper.) The hits have been optimized to low nanomolar binders that disrupt DNA binding, unlike a slide full of other (alleged) MYC inhibitors, including high-profile commercially available compounds such as MYCi361 and MYCi975.

 

I’ll close – hopefully before you stop reading. If you attended, what talks or posters stood out? And if you wish you had attended, mark your calendar for Oct. 18-21 next year, when DoT returns to Boston in time for peak leaf-peeping season.

Fragments vs DsbA: towards a chemical probe

Despite its ubiquitous use as a model organism, Escherichia coli causes nearly a million deaths each year worldwide. Antibiotics provoke rapid selection for resistance and are becoming ineffective. An interesting alternative is to inhibit virulence factors. Doing so won’t directly kill the bacteria but instead reduce its infectivity, a trait that might be subject to less evolutionary selection.

 

The oxidoreductase DsbA facilitates disulfide bond formation in other bacterial proteins and is a key regulator of resistance. Martin Scanlon’s lab at Monash University has been pursuing this enzyme for some two decades; we described some of their work in 2015. In two recent papers, he and his colleagues describe progress towards a chemical probe.

 

DsbA has more than 300 protein substrates that bind in a shallow, hydrophobic groove. The lack of deep pockets or specific recognition elements makes finding small molecule ligands particularly challenging. Three years ago we highlighted fragment screens that identified two dozen hits in this groove. Intriguingly, that screen also identified a couple fragments that bind in a cryptic pocket close to the groove. This pocket is the focus of a paper published in Angew. Chem. late last year by Martin and collaborators at Monash University, La Trobe University Bundoora, and Scripps.  

 

Crystallography revealed that compound 1 binds in a pocket that is completely enclosed by DsbA. Twenty commercial analogs were purchased and tested by protein-observed [¹⁵N,¹H]-HSQC NMR. Six bound to the protein, but NMR suggested all bound in the hydrophobic groove, not in the cryptic pocket. Undeterred, the researchers made and tested a few dozen analogs, some of which did indeed bind the cryptic pocket and also had slightly higher affinities as measured by NMR and SPR.

 

How do the fragments get inside a pocket with no apparent entrances? Computational, protein-observed NMR, SPR, and HDX experiments suggested that DsbA is dynamic and one region can open up to allow access of the fragments. Interestingly, the fragments bind preferentially to the oxidized (active) form of DsbA, a fact that makes sense given that this state is more dynamic, allowing readier access to the pocket.

 

Unfortunately, the affinity of the best fragments is only around 150 micromolar. The small size of the cryptic pocket makes further affinity improvements unlikely, so the researchers sought to break the bounds of this pocket to gain added affinity. This is the focus of a paper just published in J. Med. Chem. by Martin, Bradley Doak, and collaborators at Monash, Vernalis, University of Western Australia, and The University of Sydney.

 

The researchers first built a small set of compounds that would break out of the pocket. Compound 5 had slightly worse affinity, as measured by SPR, but crystallography confirmed that the alkyne does in fact protrude as designed. A small set of analogs led to compound 13, with mid micromolar affinity. This compound was nearly 30-fold more potent than its enantiomer, with the hydroxyl moiety displacing a conserved water to make hydrogen bond interactions with the protein.

 

To gain additional interactions in the hydrophobic groove, the researchers chose direct-to-biology, screening crude reaction mixtures without purification, an increasingly popular strategy as we noted last week. In this case the researchers used automated flow reactors, allowing air- and moisture-sensitive organometallic chemistry. A set of 92 compounds was made and tested by off-rate screening (ORS) SPR and affinity-selected mass spectrometry (ASMS). Four crude hits were remade, purified, and tested, and compound 17 came in as a low micromolar binder both by SPR and ITC. This molecule also inhibited the enzyme in a functional assay and even showed some activity in a bacterial swarming motility assay.

 

Further improvements in potency will be needed to obtain a chemical probe, let alone a drug, but these two papers describe meaningful progress. They also provide a useful reminder that proteins are far from static. Cryptic pockets are surprisingly common, and even if they are too small and enclosed to support high affinity binding, they can be used as footholds to build larger molecules.